PL3442547T3 - Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmu - Google Patents

Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmu

Info

Publication number
PL3442547T3
PL3442547T3 PL17783343.1T PL17783343T PL3442547T3 PL 3442547 T3 PL3442547 T3 PL 3442547T3 PL 17783343 T PL17783343 T PL 17783343T PL 3442547 T3 PL3442547 T3 PL 3442547T3
Authority
PL
Poland
Prior art keywords
prevention
treatment
lactobacillus reuteri
autism spectrum
spectrum disorders
Prior art date
Application number
PL17783343.1T
Other languages
English (en)
Inventor
Mauro Costa-Mattioli
Shelly Alexandra BUFFINGTON
Original Assignee
Baylor College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine filed Critical Baylor College Of Medicine
Publication of PL3442547T3 publication Critical patent/PL3442547T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL17783343.1T 2016-04-15 2017-04-15 Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmu PL3442547T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322946P 2016-04-15 2016-04-15
PCT/US2017/027827 WO2017181158A1 (en) 2016-04-15 2017-04-15 Probiotic therapies for developmental disorders and other neurological disorders

Publications (1)

Publication Number Publication Date
PL3442547T3 true PL3442547T3 (pl) 2023-10-23

Family

ID=60042831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17783343.1T PL3442547T3 (pl) 2016-04-15 2017-04-15 Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmu

Country Status (14)

Country Link
US (2) US11135252B2 (pl)
EP (2) EP3442547B1 (pl)
DK (1) DK3442547T3 (pl)
ES (1) ES2954147T3 (pl)
FI (1) FI3442547T3 (pl)
HR (1) HRP20231030T1 (pl)
HU (1) HUE062788T2 (pl)
LT (1) LT3442547T (pl)
PL (1) PL3442547T3 (pl)
PT (1) PT3442547T (pl)
RS (1) RS64503B1 (pl)
SI (1) SI3442547T1 (pl)
SM (1) SMT202300283T1 (pl)
WO (1) WO2017181158A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062788T2 (hu) * 2016-04-15 2023-12-28 Baylor College Medicine Lactobacillus reuteri MM4-1A alkalmazása az autizmus spektrumzavar kezelésében vagy megelõzésében
KR102463809B1 (ko) * 2019-05-24 2022-11-04 한국식품연구원 클로스트리디오이데스 디피실레에 항균 활성을 갖는 락토바실러스 파라카세이 WiKim0110 균주 및 이를 포함하는 조성물
JP2023511275A (ja) * 2020-01-13 2023-03-17 サイオート バイオサイエンシーズ， インコーポレイテッド 自閉症および関連障害を処置または改善するための方法
US20240050494A1 (en) * 2020-12-18 2024-02-15 The General Hospital Corporation Probiotics compositions and method of using the same to enhance growth and social function in children
CN117320566A (zh) * 2020-12-30 2023-12-29 通用医疗公司 用于治疗自闭症谱系障碍的方法和组合物
CN113073066B (zh) * 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
CN113180109B (zh) * 2021-04-16 2022-02-18 段云峰 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用
US12005044B1 (en) 2022-11-29 2024-06-11 Autism Therapeutics Inc. Treatment of autism spectrum disorders with ergothioneine, selenoneine, or combinations thereof
US20240252558A1 (en) * 2023-01-29 2024-08-01 The University Of Chicago Probiotics to rescue maternal immune activation-induced neurodevelopment deficits
JPWO2024242147A1 (pl) * 2023-05-22 2024-11-28

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
ATE477811T1 (de) 2002-10-03 2010-09-15 Neuropharmacology Services Llc Oxytocin zur behandlung von autismus und asperger-syndrom
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100063002A1 (en) * 2007-03-13 2010-03-11 Bernd Stahl Method of improving skills with a composition comprising non-digestible saccharide
US9034314B2 (en) * 2008-11-03 2015-05-19 Nestec S.A. Nutritional composition comprising probiotics and improving sleep patterns
EP2485744A4 (en) 2009-10-09 2014-01-22 Prothera Inc COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED
BR112013016929A2 (pt) * 2010-12-31 2019-09-24 Abbott Lab oligossacarídeos de leite humano para promover o crescimento de bactérias benéficas
EP2609814A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of cognitive function
EP2609813A1 (en) 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
HUE062788T2 (hu) * 2016-04-15 2023-12-28 Baylor College Medicine Lactobacillus reuteri MM4-1A alkalmazása az autizmus spektrumzavar kezelésében vagy megelõzésében

Also Published As

Publication number Publication date
EP3442547A1 (en) 2019-02-20
RS64503B1 (sr) 2023-09-29
US11135252B2 (en) 2021-10-05
SI3442547T1 (sl) 2023-11-30
DK3442547T3 (da) 2023-09-04
SMT202300283T1 (it) 2023-11-13
EP4238573A1 (en) 2023-09-06
FI3442547T3 (fi) 2023-09-05
US20190070226A1 (en) 2019-03-07
LT3442547T (lt) 2023-09-25
US20210379123A1 (en) 2021-12-09
ES2954147T3 (es) 2023-11-20
WO2017181158A1 (en) 2017-10-19
HUE062788T2 (hu) 2023-12-28
HRP20231030T1 (hr) 2023-12-22
PT3442547T (pt) 2023-09-04
EP3442547A4 (en) 2019-11-27
EP3442547B1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
SMT202300283T1 (it) Lactobacillus reuteri mm4-1a per l’uso nel trattamento o nella prevenzione dei disturbi dello spettro autistico
IL259751B (en) Polycyclic compounds and their use in the treatment of immune disorders
IL271117B (en) Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
PL3212208T3 (pl) Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia
GB2549277B (en) Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
GB2549278B (en) Use of cannabidivarin in the treatment of autism spectrum disorder
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
ZA201900869B (en) Use of probiotics in the treatment and/or prevention of atopic dermatitis
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
GB2548930B (en) Heat-inactivated Lactobacillus rhamnosis GMNL-464 for use in the prevention of halitosis
ZA201604611B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
SMT202400084T1 (it) Composizione per la prevenzione e/o il trattamento dei sintomi dell’allergia
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
IL273863B1 (en) Hemorrhoid treatment device
IL258112A (en) Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
SMT202400007T1 (it) Composizione per l'uso nel trattamento di alterazioni intestinali
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
PT3191112T (pt) Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura
ES3066523T3 (en) Pharmaceutical composition comprising vitamin k2 for use in the treatment or prevention of melanoma
GB201617715D0 (en) Methods for the treatment and prevention of ebola
EP3104940A4 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
HK40006311A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
GB201617591D0 (en) Methods for the treatment and prevention of ebola
GB201617590D0 (en) Methods for the treatment and prevention of ebola